|Other names||4'-ethynylstavudine, festinavir|
|CompTox Dashboard (EPA)|
|ECHA InfoCard||100.225.812 |
|Molar mass||248.238 g·mol−1|
|3D model (JSmol)|
This article needs to be updated. (April 2021)
Censavudine (INN), (BMS-986001) is an investigational new drug being developed by Bristol Myers-Squibb for the treatment of HIV infection. It was originally developed at Yale University.
Until 2013, censavudine has been known as festinavir, but the name was changed to avoid confusion with HIV protease inhibitors which all bear class suffix "–navir" (e.g. tipranavir, lopinavir, saquinavir etc.).
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed International Nonproprietary Names: List 110" (PDF). World Health Organization. pp. 409–410.
- ^ Wu VH, Smith RA, Masoum S, Raugi DN, Ba S, Seydi M, et al. (August 2017). "MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture". Antimicrobial Agents and Chemotherapy. 61 (8). doi:10.1128/AAC.00744-17. PMC 5527656. PMID 28559249.
- ^ Gupta SK, McComsey GA, Lombaard J, Echevarría J, Orrell C, Avihingsanon A, et al. (January 2016). "Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial". The Lancet. HIV. 3 (1): e13-22. doi:10.1016/S2352-3018(15)00231-3. hdl:1805/10552. PMID 26762988.
- ^ Alcorn K (21 December 2010). "Bristol-Myers Squibb buys festinavir, new NRTI active against MDR HIV". aidsmap.com. aidsmap. Retrieved 24 June 2011.